Skip to main content

Table 1 Description of populations used in the study

From: Metabolic system alterations in pancreatic cancer patient serum: potential for early detection

Japanese controls  
  All (n) 50
  Female (n) 20
  Male (n) 30
  Age (years, range) 63.8, 40-75
Japanese pancreatic cancer  
  All (n) 40
  Stage I (n) 4
  Stage II (n) 4
  Stage III (n) 5
  Stage IVa (n) 16
  Stage IVb (n) 11
  Collected at surgery1 (n) 24
  Not collected at surgery (n) 16
  Sample collected after treatment2 (n) 20
  Sample collected prior to treatment (n) 20
  Female (n) 14
  Male (n) 26
  Average age (years, range) 65.2, 31-79
USA Caucasian control 1  
  All ages (n) 1000
  30-39 yrs (n) 103
  40-49 yrs (n) 280
  50-59 yrs (n) 201
  60-69 yrs (n) 214
  70-80 yrs (n) 202
  Female (n) 598
  Male (n) 402
USA Caucasian control 2  
  All (n) 40
  Female (n) 8
  Male (n) 21
  Gender unknown (n) 11
  Average age (years, range) 42.7, 18-60
USA Caucasian pancreatic cancer  
  All (n) 14
  Female (n) 3
  Gender unknown (n) 11
  Average age (years, range) 70.4, 57-85
USA Caucasian IPMN  
  All, gender unknown (n) 6
  Average age (years, range) 73.0, 61-80
  1. 1Samples collected under anesthesia.
  2. 2Chemo/radiation therapy (at least one cycle).